Get the Stockscreener App
25.82
2.54%
0.64
Zenas Biopharma Inc stock is traded at $25.82, with a volume of 311.01K.
It is up +2.54% in the last 24 hours and up +24.98% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$25.18
Open:
$25.39
24h Volume:
311.01K
Relative Volume:
0.40
Market Cap:
$1.39B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.81%
1M Performance:
+24.98%
6M Performance:
+52.06%
1Y Performance:
+272.58%
1-Day Range:
$24.18
$26.86
1-Week Range:
$24.18
$26.86
52-Week Range:
$6.11
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
25.82 | 1.35B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
ZBIO SEC FilingsZenas BioPharma Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 18.8% in February - MarketBeat
What is the target price for Zenas BioPharma Inc stockPortfolio Update Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory - Insider Monkey
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 54.59% Potential Upside Awaits Investors - DirectorsTalk Interviews
Short Covering: Will Zenas BioPharma Inc outperform during market rallies - baoquankhu1.vn
A Look At Zenas BioPharma (ZBIO) Valuation As Obexelimab Shows Strong ACTRIMS 2026 Efficacy Data - Sahm
Zenas BioPharma (NASDAQ:ZBIO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Encouraging phase II trial data supported Zenas BioPharma (ZBIO) in Q4 - MSN
Encouraging Phase II Trial Data Supported Zenas BioPharma, Inc. (ZBIO) in Q4 - Finviz
Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4 - Insider Monkey
Why Zenas BioPharma (ZBIO) Is Up 24.6% After Obexelimab’s Phase 2 MS Trial SuccessAnd What's Next - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap UpHere's Why - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - PR Newswire
Street Watch: Is Zenas BioPharma Inc a good ESG investment2025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit - MarketBeat
Fundamentals Check: Is Zenas BioPharma Inc stock a good pick for beginnersJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
What Wall Street predicts for Zenas BioPharma Inc. stock priceJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - mfd.ru
Zenas BioPharma (NASDAQ:ZBIO) Director Buys $390,145.00 in Stock - MarketBeat
Hongbo Lu Buys 25,985 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Director Buys $109,657.60 in Stock - MarketBeat
Zenas BioPharma Adopts Amended Short-Term Incentive Plan - TipRanks
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 56% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
Zenas BioPharma (NASDAQ:ZBIO) Trading 13.8% HigherWhat's Next? - MarketBeat
Will Zenas BioPharma Inc. outperform during market ralliesWeekly Trade Analysis & Low Risk Investment Opportunities - mfd.ru
Can Zenas BioPharma Inc. be the next market leaderTreasury Yields & Community Consensus Stock Picks - mfd.ru
ZBIO: Obexelimab shows strong efficacy, safety, and commercial promise in IgG4-RD and beyond - TradingView
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions - Investing.com Nigeria
Zenas BioPharma approves 2026 inducement plan - MSN
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions By Investing.com - Investing.com Australia
Zenas BioPharma Meets Key Goal In Phase 2 MoonStone Trial Of Obexelimab In R/Multiple Sclerosis - RTTNews
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone ... - Bluefield Daily Telegraph
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - GlobeNewswire
Zenas Biopharma Announces Late-Breaking Platform Presentation Of Results From Phase 2 Moonstone Trial Of Obexelimab In Relapsing Multiple Sclerosis At Actrims Forum 2026 - TradingView
Insider Trends: Can Zenas BioPharma Inc be the next market leaderJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - MSN
Does Zenas BioPharma (ZBIO) CEO’s Million‑Dollar Share Buy Reframe Management Credibility After Recent Setbacks? - Sahm
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Phase 3 INDIGO Data And CEO Share Purchase - Sahm
Commit To Purchase Zenas Biopharma At $12.50, Earn 21.9% Annualized Using Options - Nasdaq
Zenas Bio rises after insider purchase by CEO (ZBIO:NASDAQ) - Seeking Alpha
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - marketscreener.com
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zenas BioPharma (ZBIO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
A Big Boss Bet on Zenas BioPharma’s Future - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) CEO Buys 57,000 Shares - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Shares Up 8.9%Here's Why - MarketBeat
Chipmakers Recap: What is the target price for Zenas BioPharma Inc stockJuly 2025 Catalysts & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - ChartMill
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Allen Patricia L | Director |
Feb 12 '26 |
Buy |
24.85 |
15,700 |
390,088 |
15,700 |
| Allen Patricia L | Director |
Feb 13 '26 |
Buy |
26.36 |
4,160 |
109,658 |
19,860 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 02 '26 |
Buy |
17.96 |
57,000 |
1,023,720 |
423,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 07 '26 |
Buy |
16.38 |
50,000 |
819,000 |
316,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 08 '26 |
Buy |
16.30 |
30,000 |
489,000 |
346,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 09 '26 |
Buy |
16.55 |
20,000 |
331,000 |
366,155 |
| Nunn Jason Raleigh | Director |
Oct 09 '25 |
Buy |
19.00 |
63,158 |
1,200,002 |
1,173,395 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Oct 09 '25 |
Buy |
19.00 |
126,315 |
2,399,985 |
1,917,895 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
19.00 |
105,265 |
2,000,035 |
1,832,669 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
20.85 |
11,990 |
249,992 |
11,990 |
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):